{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-057146","form_type":"8-K","ticker":"ATRA","cik":"0001604464","company_name":"Atara Biotherapeutics, Inc.","filed_at":"2023-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.744857+00:00","generated_at":"2026-06-09T02:38:39.630898+00:00","sec_items":["1.01","2.02","2.05","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Atara expands tab-cel partnership worth up to $640M, cuts workforce 30%, Q3 loss $69.8M","bullets":["Expanded global tab-cel deal with Pierre Fabre: up to $640M in payments, ~$30M upfront and $100M regulatory milestones, plus tiered double-digit royalties.","Workforce reduction of ~30% to extend cash runway into Q3 2025; $7M in severance charges expected.","Q3 net loss $69.8M ($0.66/sh) vs $84.1M ($0.82/sh) in prior year; cash, equivalents, and investments $102.4M at Sep 30.","ATA188 Phase 2 EMBOLD primary analysis on track for early Nov; focus shifts to ATA188 and AlloCAR-T programs."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-057146","json":"https://secwatch.observer/filing/0000950170-23-057146.json","markdown":"https://secwatch.observer/filing/0000950170-23-057146.md","text":"https://secwatch.observer/filing/0000950170-23-057146.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604464/000095017023057146/0000950170-23-057146-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604464/000095017023057146/atra-20231031.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T02:38:39.630898+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b5cbd991dcad69e05213bdacf4af0cd0fc80d225","claim":"Atara Biotherapeutics, Inc. reported third quarter ended September 30, 2023 results: net income net loss of $69.8 million, EPS $0.66 per share.","evidence_excerpt":"Atara reported a net loss of $69.8 million, or $0.66 per share for the third quarter 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1604464/000095017023057146/0000950170-23-057146-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Net income","value":"net loss of $69.8 million"},{"label":"EPS","value":"$0.66 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"a70684b19524af01bda4b1a1751cc8151e181978","claim":"Atara Biotherapeutics, Inc. amended Amended and Restated Commercialization Agreement with Pierre Fabre Medicament valued at $20 million (effective 2023-10-31).","evidence_excerpt":"On October 31, 2023, Atara Biotherapeutics, Inc. (the “Company”) entered into an Amended and Restated Commercialization Agreement (the “A&R Commercialization Agreement”) with Pierre Fabre Medicament (“Pierre Fabre”), which amends and restates that certain Commercialization Agreement dated October 2, 2021, as amended on September 27, 2022 (the “Original Commercialization Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1604464/000095017023057146/0000950170-23-057146-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Pierre Fabre Medicament"},{"label":"Value","value":"$20 million"},{"label":"Effective","value":"2023-10-31"}],"fact_type":"material_agreement"},{"claim_id":"b5012781bd8c28ebd8f491a0ebc2f0bb3a23acb6","claim":"Atara Biotherapeutics, Inc. announced a restructuring with charges of approximately $7.0 million in total for severance and related benefits (approximately 30% of its current employees).","evidence_excerpt":"On November 1, 2023, the Company announced a reduction in its workforce that will impact approximately 30% of its current employees. The Company expects to substantially complete the workforce reduction by December 31, 2023. The Company expects to recognize approximately $7.0 million in total for severance and related benefits for employees laid off under the reduction in force.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1604464/000095017023057146/0000950170-23-057146-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $7.0 million in total for severance and related benefits"},{"label":"Headcount","value":"approximately 30% of its current employees"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}